Evidence map›Paper›PMID 41672942›Full record

ArticleChinese medical journal2026

Disease burden of hematological malignancies worldwide, in China and in the United States based on the GLOBOCAN 2022 and Global Burden of Disease 2021 data.

Minghao Lin, Wei Sun, Xiaojun Huang, Xiangyu Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Minghao LinPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Wei SunPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Xiangyu ZhaoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHematological malignancies are a heterogeneous group of diseases caused by disruptions in normal hematopoietic function. This study aimed to evaluate the global burden of hematological malignancies, including Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), and leukemia, with a focus on comparing China and the United States (US).

methodsData from the GLOBOCAN 2022 and Global Burden of Disease (GBD) 2021 were used to estimate the incidence and mortality of hematological malignancies. This study analyzed the age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and estimated annual percentage change (EAPC) to compare trends over time, and risk factors were also assessed.

resultsIn 2022, there were 1,311,104 new cases and 700,205 deaths from hematological malignancies worldwide. Among them, there were 197,438 new cases and 110,367 deaths in China, whereas in the US, there were 181,894 new cases and 58,283 deaths. NHL was the most common type of hematological malignancy, followed by leukemia, MM, and HL globally. Males had higher incidence and mortality rates than females. Compared with China, the US had higher ASIR (30.65 vs . 9.51 per 100,000) and ASMR (7.33 vs . 4.73 per 100,000) in 2022. Additionally, the ASIR and ASMR were higher in very high human development index (HDI) countries than in low HDI countries. The incidence of NHL and MM has increased over time, whereas the incidence of HL and leukemia has decreased worldwide. The ASMRs for all types of hematological malignancies, except for MM, have been declining. Furthermore, we identified risk factors contributing to hematological malignancy disability-adjusted life years (DALYs) and deaths, including smoking, high body mass index, and occupational exposure to benzene or formaldehyde. The predicted number of new cases of and deaths from hematological malignancies gradually increased from 2022 to 2050.

conclusionsThis study highlights the serious burden of hematological malignancies worldwide, in China, and in the US, emphasizing the urgency for effective prevention and treatment strategies.

Indexed as

Hematologic NeoplasmsChinaFemaleGlobal Burden of DiseaseHumansIncidenceLeukemiaMaleRisk FactorsUnited StatesChinaGBDGlobal burden of diseaseGLOBCANHematological malignanciesIncidenceMortalityTrendsUS

Identifiers

PMID41672942
PMCPMC13043260

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.